Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing...
Transcript of Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing...
![Page 1: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/1.jpg)
1
Research Versus Manufacturing14th DEA Pharmaceutical
ConferencePortland, OR
Susan M. Carr
Deputy Chief
Drug Enforcement Administration
Office of Diversion Control
Drug and Chemical Evaluation Section
![Page 2: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/2.jpg)
2
Research vs. Manufacturing
Research and Manufacturing are designated as independent activities for which separate registrations are required with the DEA
21 CFR 1301.13 (e) (1) describes specific coincident activities for which separate registrations are not required
![Page 3: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/3.jpg)
3
Researcher Coincident Activities21 CFR 1301.13(e)(1)
Schedule I:
manufacture or import substance for which registration was issued and set forth in protocol (21 CFR 1301.18)
distribute to persons registered to conduct research or chemical analysis with such substance
![Page 4: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/4.jpg)
4
Researcher Coincident Activities21 CFR 1301.13(e)(1)
Schedules II through V:
chemical analysis
manufacture as set forth in statement
import substances for research purposes
distribute to persons registered to conduct research, chemical analysis, instructional activities
![Page 5: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/5.jpg)
5
Research Activities
Small amounts may be manufactured if the quantities are set forth in statement filed with the application for registration, AND
The purpose as set forth in statement is to develop synthesis procedures or other research not related to dosage form development
![Page 6: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/6.jpg)
6
Manufacturer Coincident Activities21 CFR 1301.13(e)(1)
Schedule I through V:
distribute a substance or class for which registration was issued
Schedule II through V:
conduct chemical analysis and preclinical research with substances authorized to manufacture
![Page 7: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/7.jpg)
7
Manufacturing Activities
Purpose is to satisfy regulatory requirements such as FDA submissions or good manufacturing practice
Establishing manufacturing processes and procedures (pilot, scale up, reformulation studies etc.)
Development including bioavailability, formulation, stability and validation studies
![Page 8: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/8.jpg)
8
Conclusion
Once manufacturing moves beyond the scope of the research and becomes product development, those manufacturing activities are no longer considered to be coincident.
Must meet requirements for registration as a manufacturer
![Page 9: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/9.jpg)
9
Historical Determinations
Validation Dosage forms for
approval andtesting, includingclinical trials
Stability
Exhibit batches
Rework processes Granulation
development
Process parameters in laboratory
Adhesive studies
Laboratory testing
Dosage release rate studies
Conducting Clinical trials
Synthesis route
Manufacturing Research
![Page 10: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/10.jpg)
10
Who to ask for determinations
DEA Headquarters
Office of Diversion/ODE
Attn: Christine A. Sannerud, Ph.D., Chief
2401 Jefferson Davis Highway
Alexandria, VA 22301
![Page 11: Research Versus Manufacturing 14th DEA Pharmaceutical · 2013. 7. 8. · Research vs Manufacturing - 14th Pharmaceutical Industry Conference Oct. 2009 Portland OR Author: DEA Office](https://reader035.fdocuments.us/reader035/viewer/2022071003/5fc02d2bed3913244f6df113/html5/thumbnails/11.jpg)
11
Questions?